Literature DB >> 22190312

Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials.

Patricia L Andres1, Linda M Skerry, Theodore L Munsat, Brenda J Thornell, Jackie Szymonifka, David A Schoenfeld, Merit E Cudkowicz.   

Abstract

INTRODUCTION: Strength measures with reduced variability and higher sensitivity could improve efficiency in clinical trials of amyotrophic lateral sclerosis (ALS). The Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure force in 12 muscle groups. In this study we evaluate the reliability and validity of the ATLIS testing protocol.
METHODS: Twenty healthy adults and 10 patients with ALS were tested twice by the same or by different evaluators to determine test-retest and interrater reliability. Twenty healthy adults were examined using ATLIS and a well-validated strength testing protocol (TQNE) to assess criterion-based validity.
RESULTS: Mean absolute variation between tests was 8.6%, and intraclass correlation coefficients for each muscle group were high (range 0.82-0.99). The Pearson correlation coefficient of mean ATLIS and TQNE scores was 0.90. A subject survey demonstrated high user acceptance of ATLIS.
CONCLUSIONS: ATLIS is convenient for patients and evaluators, produces precise strength measurements, and is easily moved between examining rooms.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22190312     DOI: 10.1002/mus.22253

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

1.  Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system.

Authors:  Jeremy M Shefner; Seward B Rutkove; James B Caress; Michael Benatar; William S David; Michael S Cartwright; Eric A Macklin; Jose L Bohorquez
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-09-28       Impact factor: 4.092

Review 2.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 3.  Strength Testing in Motor Neuron Diseases.

Authors:  Jeremy M Shefner
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Upper extremity 3-dimensional reachable workspace assessment in amyotrophic lateral sclerosis by Kinect sensor.

Authors:  Bjorn Oskarsson; Nanette C Joyce; Evan De Bie; Alina Nicorici; Ruzena Bajcsy; Gregorij Kurillo; Jay J Han
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 5.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

6.  Outcome measures in amyotrophic lateral sclerosis clinical trials.

Authors:  Sabrina Paganoni; Merit Cudkowicz; James D Berry
Journal:  Clin Investig (Lond)       Date:  2014

7.  A pilot trial of RNS60 in amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Mohamad J Alshikho; Sarah Luppino; James Chan; Lindsay Pothier; David Schoenfeld; Patricia L Andres; Suma Babu; Nicole R Zürcher; Marco L Loggia; Robert L Barry; Silvia Luotti; Giovanni Nardo; Maria Chiara Trolese; Serena Pantalone; Caterina Bendotti; Valentina Bonetto; Fabiola De Marchi; Bruce Rosen; Jacob Hooker; Merit Cudkowicz; Nazem Atassi
Journal:  Muscle Nerve       Date:  2018-12-26       Impact factor: 3.217

Review 8.  Assessment of Motor Units in Neuromuscular Disease.

Authors:  Robert D Henderson; Pamela A McCombe
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

9.  Patients with ALS show highly correlated progression rates in left and right limb muscles.

Authors:  David J Rushton; Patricia L Andres; Peggy Allred; Robert H Baloh; Clive N Svendsen
Journal:  Neurology       Date:  2017-06-09       Impact factor: 9.910

10.  Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study.

Authors:  Luis Garcia-Gancedo; Madeline L Kelly; Arseniy Lavrov; Jim Parr; Rob Hart; Rachael Marsden; Martin R Turner; Kevin Talbot; Theresa Chiwera; Christopher E Shaw; Ammar Al-Chalabi
Journal:  JMIR Mhealth Uhealth       Date:  2019-12-20       Impact factor: 4.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.